|View printer-friendly version|
|February 20, 2018 11:03 a.m.|
|Teva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn® in the United States|
Minocycline Hydrochloride Extended-Release Tablets are a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
“The launch of these two strengths of our generic version of Solodyn® brings an effective, affordable treatment option to patients who are managing this condition, and marks our ninth generic medicine in the tetracycline category,”2 said Brendan O’Grady, Executive Vice President and Head of North America Commercial at Teva.
With nearly 600 generic medicines available, Teva has the largest
Solodyn® Extended Release Tablets, 65 and 115 mg, had annual
sales of approximately
About Minocycline Hydrochloride Extended-Release Tablets
Minocycline Hydrochloride Extended-Release Tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Limitations of Use: Minocycline Hydrochloride Extended-Release Tablets did not demonstrate any effect on non-inflammatory acne lesions. Safety of Minocycline Hydrochloride Extended-Release Tablets has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, Minocycline Hydrochloride Extended-Release Tablets should be used only as indicated.
Important Safety Information
Minocycline Hydrochloride Extended-Release Tablets are contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
MINOCYCLINE, LIKE OTHER TETRACYCLINE-CLASS DRUGS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS. Minocycline Hydrochloride Extended-Release Tablets should not be used during pregnancy or by individuals of either gender who are attempting to conceive a child.
TETRACYCLINE-CLASS DRUGS SHOULD NOT BE USED DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY AND UP TO 8 YEARS OF AGE) AS THEY MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH.
Other serious adverse reactions reported with minocycline use or associated with the use of tetracycline-class drugs include pseudomembranous colitis; hepatotoxicity; excessive systemic accumulation of drug and possible liver toxicity in patients with renal impairment; central nervous system effects, including light-headedness, dizziness or vertigo; pseudotumor cerebri (benign intracranial hypertension); autoimmune syndromes; photosensitivity; anaphylaxis, serious skin reactions (e.g., Stevens Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome; tissue hyperpigmentation; development of drug-resistant bacteria; and superinfection.
In clinical trials, the most commonly observed adverse reactions (incidence ≥ 5%) were headache, fatigue, dizziness, and pruritus.
For more information, please see accompanying Full Prescribing Information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch and potential benefits of Teva's generic version of Solodyn®, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”) and in our other filings with the U.S. Securities and Exchange Commission (the “SEC”). Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to rely on these forward-looking statements. You are advised to consult any additional disclosures we make in our reports to the SEC on Form 6-K, as well as the cautionary discussion of risks and uncertainties under “Risk Factors” in our Annual Report. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those listed could also materially and adversely affect us. This discussion is provided as permitted by the Private Securities Litigation Reform Act of 1995.
1 Solodyn® is a registered trademark of
Teva Pharmaceutical Industries Ltd.